EA201590907A1 - Усиленные полиамином составы для ионтофореза соединения триптана - Google Patents

Усиленные полиамином составы для ионтофореза соединения триптана

Info

Publication number
EA201590907A1
EA201590907A1 EA201590907A EA201590907A EA201590907A1 EA 201590907 A1 EA201590907 A1 EA 201590907A1 EA 201590907 A EA201590907 A EA 201590907A EA 201590907 A EA201590907 A EA 201590907A EA 201590907 A1 EA201590907 A1 EA 201590907A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iontophreesis
triptane
polyamin
compounds
sumatriptan succinate
Prior art date
Application number
EA201590907A
Other languages
English (en)
Other versions
EA026988B1 (ru
Inventor
Терри Б. Сибри
Майкл Хорстманн
Мохаммад Самети
Original Assignee
Тэва Фармасьютикалс Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тэва Фармасьютикалс Интернэшнл Гмбх filed Critical Тэва Фармасьютикалс Интернэшнл Гмбх
Publication of EA201590907A1 publication Critical patent/EA201590907A1/ru
Publication of EA026988B1 publication Critical patent/EA026988B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к ионтофоретическому трансдермальному пластырю для доставки суматриптана сукцината, содержащему анодный резервуар и катодный резервуар, при этом анодный резервуар содержит от 3,0 до 5,0% суматриптана сукцината и другие компоненты, определенные в формуле изобретения. Ионтофоретический трансдермальный пластырь согласно изобретению позволяет вводить высокие дозы суматриптана сукцината, не вызывая при этом значительного раздражения кожи.
EA201590907A 2008-06-19 2008-10-30 Усиленные полиамином составы для ионтофореза соединения триптана EA026988B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/214,555 US8366600B2 (en) 2008-06-19 2008-06-19 Polyamine enhanced formulations for triptan compound iontophoresis

Publications (2)

Publication Number Publication Date
EA201590907A1 true EA201590907A1 (ru) 2016-02-29
EA026988B1 EA026988B1 (ru) 2017-06-30

Family

ID=41431954

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100055A EA023339B1 (ru) 2008-06-19 2008-10-30 Усиленные полиамином составы для ионтофореза соединения триптана
EA201590907A EA026988B1 (ru) 2008-06-19 2008-10-30 Усиленные полиамином составы для ионтофореза соединения триптана

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201100055A EA023339B1 (ru) 2008-06-19 2008-10-30 Усиленные полиамином составы для ионтофореза соединения триптана

Country Status (12)

Country Link
US (3) US8366600B2 (ru)
EP (1) EP2296597A4 (ru)
JP (2) JP5931439B2 (ru)
CN (2) CN102065807B (ru)
AU (2) AU2008358026B2 (ru)
CA (1) CA2727926A1 (ru)
EA (2) EA023339B1 (ru)
HK (1) HK1201763A1 (ru)
IL (1) IL209755A (ru)
MX (1) MX2010013645A (ru)
WO (1) WO2009154648A1 (ru)
ZA (1) ZA201008859B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3308777A1 (en) * 2008-06-19 2018-04-18 LTS Lohmann Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
US8845612B2 (en) * 2009-08-10 2014-09-30 Nupathe Inc. Methods for iontophoretically treating nausea and migraine
ES2955255T3 (es) 2016-03-25 2023-11-29 Aminex Therapeutics Inc Poliaminas biodisponibles
WO2018006069A1 (en) 2016-06-30 2018-01-04 Teva Pharmaceuticals International Gmbh Improved formulations for transdermal pharmaceutical systems
BR112020010146A2 (pt) 2017-12-20 2020-10-13 Lts Lohmann Therapie-Systeme Ag composição frigoestável para fornecimento transdérmico iontoforético de um composto de triptano
EP3727330A1 (en) * 2017-12-20 2020-10-28 LTS Lohmann Therapie-Systeme AG Frigostable composition for iontophoretic transdermal delivery of a triptan compound
JP2023545674A (ja) 2020-09-30 2023-10-31 アミネックス セラピューティクス， インコーポレイテッド ポリアミン輸送阻害剤およびｄｆｍｏの配合原薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4856188A (en) 1984-10-12 1989-08-15 Drug Delivery Systems Inc. Method for making disposable and/or replenishable transdermal drug applicators
US5605536A (en) 1983-08-18 1997-02-25 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US5651768A (en) 1983-08-18 1997-07-29 Drug Delivery Systems, Inc. Transdermal drug applicator and electrodes therefor
US4822802A (en) 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4927408A (en) 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
DE4014913C2 (de) 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
ATE160510T1 (de) 1992-06-02 1997-12-15 Alza Corp Abgabevorrichtung zur elektrischen übertragung von arzneimitteln
US5807571A (en) 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5458569A (en) 1993-06-08 1995-10-17 Becton Dickinson And Company Wearable iontophoresis system
US5533971A (en) 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
EP0643981B1 (en) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. A matrix for iontophoreses
US5697896A (en) 1994-12-08 1997-12-16 Alza Corporation Electrotransport delivery device
IE960312A1 (en) 1995-06-02 1996-12-11 Alza Corp An electrotransport delivery device with voltage boosting¹circuit
US6425892B2 (en) 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
AU699774B2 (en) 1995-06-05 1998-12-17 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6216033B1 (en) 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5941843A (en) 1996-07-12 1999-08-24 Empi, Inc. Iontophoresis electrode
US5882677A (en) * 1997-09-30 1999-03-16 Becton Dickinson And Company Iontophoretic patch with hydrogel reservoir
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
JP4414517B2 (ja) * 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US6421561B1 (en) 1999-12-30 2002-07-16 Birch Point Medical, Inc. Rate adjustable drug delivery system
DE10035891A1 (de) * 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6653014B2 (en) 2001-05-30 2003-11-25 Birch Point Medical, Inc. Power sources for iontophoretic drug delivery systems
ES2312585T3 (es) 2001-06-05 2009-03-01 Ronald Aung-Din Terapia contra la migraña por via topica.
US20030065285A1 (en) * 2001-07-23 2003-04-03 Higuchi William I. Method and apparatus for increasing flux during reverse iontophoresis
AU2003280136A1 (en) 2002-06-28 2004-01-19 Alza Corporation A reservoir for use in an electrotransport drug delivery device
US6745071B1 (en) 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
US20040242770A1 (en) 2003-04-16 2004-12-02 Feldstein Mikhail M. Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
US7856263B2 (en) 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
AU2006297156A1 (en) 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoresis method and apparatus for systemic delivery of active agents
US20070093789A1 (en) * 2005-09-30 2007-04-26 Transcutaneous Technologies Inc. Iontophoresis apparatus and method for delivery of angiogenic factors to enhance healing of injured tissue
NZ596498A (en) 2006-04-13 2013-05-31 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
EP3308777A1 (en) 2008-06-19 2018-04-18 LTS Lohmann Therapie-Systeme AG Composition for transdermal delivery of cationic active agents

Also Published As

Publication number Publication date
ZA201008859B (en) 2016-03-30
JP2014237675A (ja) 2014-12-18
AU2008358026B2 (en) 2015-06-18
EP2296597A4 (en) 2013-10-16
CN102065807B (zh) 2014-06-25
HK1201763A1 (en) 2015-09-11
JP2011524901A (ja) 2011-09-08
WO2009154648A1 (en) 2009-12-23
US20130245535A1 (en) 2013-09-19
AU2008358026A1 (en) 2009-12-23
IL209755A0 (en) 2011-02-28
JP5931439B2 (ja) 2016-06-08
US8366600B2 (en) 2013-02-05
IL209755A (en) 2014-06-30
EA201100055A1 (ru) 2011-08-30
AU2015224400B2 (en) 2017-06-01
AU2015224400A1 (en) 2015-10-29
US20090318847A1 (en) 2009-12-24
CA2727926A1 (en) 2009-12-23
MX2010013645A (es) 2011-02-15
JP6002179B2 (ja) 2016-10-05
EP2296597A1 (en) 2011-03-23
EA023339B1 (ru) 2016-05-31
EA026988B1 (ru) 2017-06-30
CN104027885A (zh) 2014-09-10
US20170112779A1 (en) 2017-04-27
CN102065807A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
EA201590907A1 (ru) Усиленные полиамином составы для ионтофореза соединения триптана
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
MX353713B (es) Composiciones de administracion dermica y metodos.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
EA201690033A3 (ru) Морфинановые соединения
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MX2018008467A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
CR11631A (es) Paramyxovirus eficaz como antitumoral
WO2008116004A3 (en) Transdermal patch and method for delivery of vitamin b12
RU2013112765A (ru) Улучшенная трансбуккальная система доставки лекарственного средства и композиции
CO6321270A2 (es) Nuevas posibilidades de lucha contra la giardiasis
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
CY1120920T1 (el) Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο
PE20051035A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida
MX2020013707A (es) Metodos y aplicadores para tratar afecciones vaginales.
EA201200754A1 (ru) Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение
MX2010006019A (es) Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU